Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment [2]

Leukemia

Volumn 20, Issue 6, 2006, Pages 1159-1161

  Trbusek, M ^a   Malcikova, J ^a   Smardova, J ^a   Kuhrova, V ^a   Mentzlova, D ^a   Francova, H ^a   Bukovska, S ^a   Svitakova, M ^a   Kuglik, P ^a   Linkova, V ^a   Doubek, M ^a   Brychtova, Y ^a   Zacal, J ^a   Kujickova, J ^a   Pospisilova, S ^a   Dvorakova, D ^a   Vorlicek, J ^a   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53;

ADULT; ALTERNATIVE RNA SPLICING; B CELL LEUKEMIA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; LETTER; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ISOLATION; WESTERN BLOTTING; WILD TYPE;

EID: 33744503387     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404195     Document Type: Letter

References (8)

1. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
2. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
3. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822.
4. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
5. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, Atkinson S, Kaczmarek P, Morilla RM et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004; 5: 47-54.
6. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-3967.
7. Smardova J, Pavlova S, Koukalova H. Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002; 8: 245-251.
8. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996; 12: 813-818.